vs
AVANOS MEDICAL, INC.（AVNS）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Ribbon Communications Inc.的1.1倍（$180.9M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs -0.7%，领先55.5%），AVANOS MEDICAL, INC.同比增速更快（0.7% vs -10.3%），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs -8.1%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
AVNS vs RBBN — 直观对比
营收规模更大
AVNS
是对方的1.1倍
$162.6M
营收增速更快
AVNS
高出11.0%
-10.3%
净利率更高
RBBN
高出55.5%
-0.7%
两年增速更快
AVNS
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $162.6M |
| 净利润 | $-1.3M | $89.1M |
| 毛利率 | 47.5% | 42.9% |
| 营业利润率 | 1.4% | 37.6% |
| 净利率 | -0.7% | 54.8% |
| 营收同比 | 0.7% | -10.3% |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $-0.02 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $180.9M | $227.3M | ||
| Q3 25 | $177.8M | $215.4M | ||
| Q2 25 | $175.0M | $220.6M | ||
| Q1 25 | $167.5M | $181.3M | ||
| Q4 24 | $179.6M | $251.4M | ||
| Q3 24 | $170.4M | $210.2M | ||
| Q2 24 | $171.7M | $192.6M |
净利润AVNSRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-12.1M | ||
| Q2 25 | $-76.8M | $-11.1M | ||
| Q1 25 | $6.6M | $-26.2M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $-13.4M | ||
| Q2 24 | $1.8M | $-16.8M |
毛利率AVNSRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 47.5% | 53.3% | ||
| Q3 25 | 48.4% | 50.1% | ||
| Q2 25 | 52.6% | 49.6% | ||
| Q1 25 | 53.6% | 45.4% | ||
| Q4 24 | 54.6% | 55.7% | ||
| Q3 24 | 54.5% | 52.1% | ||
| Q2 24 | 55.7% | 50.8% |
营业利润率AVNSRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | 1.4% | 4.1% | ||
| Q3 25 | 0.1% | 1.3% | ||
| Q2 25 | -42.6% | 1.9% | ||
| Q1 25 | 6.1% | -10.8% | ||
| Q4 24 | -233.0% | 13.2% | ||
| Q3 24 | 7.0% | -0.4% | ||
| Q2 24 | 3.7% | -1.0% |
净利率AVNSRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -5.6% | ||
| Q2 25 | -43.9% | -5.0% | ||
| Q1 25 | 3.9% | -14.5% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | -6.4% | ||
| Q2 24 | 1.0% | -8.7% |
每股收益（稀释后）AVNSRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $-0.02 | $0.50 | ||
| Q3 25 | $-0.03 | $-0.07 | ||
| Q2 25 | $-1.66 | $-0.06 | ||
| Q1 25 | $0.14 | $-0.15 | ||
| Q4 24 | $-8.64 | $0.05 | ||
| Q3 24 | $0.09 | $-0.08 | ||
| Q2 24 | $0.04 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $67.6M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $419.1M |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $89.8M | $96.4M | ||
| Q3 25 | $70.5M | $74.8M | ||
| Q2 25 | $90.3M | $60.5M | ||
| Q1 25 | $97.0M | $71.2M | ||
| Q4 24 | $107.7M | $87.8M | ||
| Q3 24 | $89.0M | $37.2M | ||
| Q2 24 | $92.2M | $64.6M |
总债务AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $342.1M | ||
| Q3 25 | $93.4M | $344.3M | ||
| Q2 25 | $95.7M | $346.5M | ||
| Q1 25 | $98.0M | $347.4M | ||
| Q4 24 | $125.3M | $348.3M | ||
| Q3 24 | $152.6M | $349.1M | ||
| Q2 24 | $164.9M | $350.0M |
股东权益AVNSRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $778.2M | $449.0M | ||
| Q3 25 | $778.0M | $360.1M | ||
| Q2 25 | $776.3M | $370.4M | ||
| Q1 25 | $839.4M | $381.8M | ||
| Q4 24 | $828.5M | $404.6M | ||
| Q3 24 | $1.2B | $395.5M | ||
| Q2 24 | $1.2B | $405.0M |
总资产AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.1B |
负债/权益比AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | 0.76× | ||
| Q3 25 | 0.12× | 0.96× | ||
| Q2 25 | 0.12× | 0.94× | ||
| Q1 25 | 0.12× | 0.91× | ||
| Q4 24 | 0.15× | 0.86× | ||
| Q3 24 | 0.12× | 0.88× | ||
| Q2 24 | 0.13× | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | — |
| 自由现金流经营现金流 - 资本支出 | $21.3M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 3.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | — |
8季度趋势，按日历期对齐
经营现金流AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $29.2M | ||
| Q3 25 | $14.0M | $26.5M | ||
| Q2 25 | $6.8M | $-795.0K | ||
| Q1 25 | $25.7M | $-3.5M | ||
| Q4 24 | $57.9M | $61.8M | ||
| Q3 24 | $23.0M | $-14.8M | ||
| Q2 24 | $27.8M | $-9.8M |
自由现金流AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $27.3M | ||
| Q3 25 | $7.0M | $21.0M | ||
| Q2 25 | $-4.2M | $-6.5M | ||
| Q1 25 | $19.0M | $-15.7M | ||
| Q4 24 | $53.1M | $53.8M | ||
| Q3 24 | $20.0M | $-23.7M | ||
| Q2 24 | $21.9M | $-12.9M |
自由现金流率AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 3.9% | 9.7% | ||
| Q2 25 | -2.4% | -2.9% | ||
| Q1 25 | 11.3% | -8.7% | ||
| Q4 24 | 29.6% | 21.4% | ||
| Q3 24 | 11.7% | -11.3% | ||
| Q2 24 | 12.8% | -6.7% |
资本支出强度AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 0.9% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 4.0% | 6.7% | ||
| Q4 24 | 2.7% | 3.2% | ||
| Q3 24 | 1.8% | 4.2% | ||
| Q2 24 | 3.4% | 1.6% |
现金转化率AVNSRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
